Taro Pharmaceuticals U.S.A., Inc. Issues Voluntary Nationwide Recall of Lamotrigine Tablets USP, 100 mg, 100 Count Bottles


Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling one (1) lot of Lamotrigine 100 mg Tablets, Lot # 331771 (expiration date June 2021) in 100 count bottles, NDC 51672-4131-1 to the consumer level. (US Food Recalls) More More

Similar stories

Taro to Announce Third Quarter Results on February 3, 2020 - Business Wire

Taro to Announce Third Quarter Results on February 3, 2020  Business Wire

Posted on 28 January 2020 | 3:00 am | Google News

Recon: Startup EQRx Raises $200M in Effort to Bring Cheaper Drugs to Market; Incyte Buys Rights to MorphoSys CAR-T Rival - Regulatory Focus

Recon: Startup EQRx Raises $200M in Effort to Bring Cheaper Drugs to Market; Incyte Buys Rights to MorphoSys CAR-T Rival  Regulatory Focus

Posted on 13 January 2020 | 3:00 am | Google News

Taro Pharmaceuticals U.S.A., Inc. Issues Voluntary Nationwide Recall of Lamotrigine Tablets USP, 100 mg, 100 Count Bottles - FDA.gov

Taro Pharmaceuticals U.S.A., Inc. Issues Voluntary Nationwide Recall of Lamotrigine Tablets USP, 100 mg, 100 Count Bottles  FDA.gov

Posted on 10 January 2020 | 3:00 am | Google News

Taro Announces Final Results of Its Tender Offer - Business Wire

Taro Announces Final Results of Its Tender Offer  Business Wire

Posted on 19 December 2019 | 3:00 am | Google News

Taro Announces Resignation of Chief Financial Officer - Business Wire

Taro Announces Resignation of Chief Financial Officer  Business Wire

Posted on 6 December 2019 | 3:00 am | Google News

Taro Announces Commencement of Tender Offer to Repurchase up to $225 Million in Value of Its Ordinary Shares - Business Wire

Taro Announces Commencement of Tender Offer to Repurchase up to $225 Million in Value of Its Ordinary Shares  Business Wire

Posted on 15 November 2019 | 3:00 am | Google News

Copyright © 2020 LastMinuteStuff.com | Contact info